Details

Autor(en) / Beteiligte

• Mauri, Tommaso
• Foti, Giuseppe
• Fornari, Carla
• Grasselli, Giacomo
• Pinciroli, Riccardo
• Lovisari, Federica
• Tubiolo, Daniela
• Volta, Carlo Alberto
• Spadaro, Savino
• Rona, Roberto
• Rondelli, Egle
• Navalesi, Paolo
• Garofalo, Eugenio
• Knafelj, Rihard
• Gorjup, Vojka
• Colombo, Riccardo
• Cortegiani, Andrea
• Zhou, Jian-Xin
• D'Andrea, Rocco
• Calamai, Italo
• Vidal González, Ánxela
• Roca, Oriol
• Grieco, Domenico Luca
• Jovaisa, Tomas
• Bampalis, Dimitrios
• Becher, Tobias
• Battaglini, Denise
• Ge, Huiqing
• Luz, Mariana
• Constantin, Jean-Michel
• Ranieri, Marco
• Guerin, Claude
• Mancebo, Jordi
• Pelosi, Paolo
• Fumagalli, Roberto
• Brochard, Laurent
• Pesenti, Antonio

Titel

Sigh in Patients With Acute Hypoxemic Respiratory Failure and ARDS: The PROTECTION Pilot Randomized Clinical Trial

Ist Teil von

• Chest, 2021-04, Vol.159 (4), p.1426-1436

Ort / Verlag

United States: The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Sigh is a cyclic brief recruitment maneuver: previous physiologic studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity, and increase release of surfactant. Is the clinical application of sigh during pressure support ventilation (PSV) feasible? We conducted a multicenter noninferiority randomized clinical trial on adult intubated patients with acute hypoxemic respiratory failure or ARDS undergoing PSV. Patients were randomized to the no-sigh group and treated by PSV alone, or to the sigh group, treated by PSV plus sigh (increase in airway pressure to 30 cm H O for 3 s once per minute) until day 28 or death or successful spontaneous breathing trial. The primary end point of the study was feasibility, assessed as noninferiority (5% tolerance) in the proportion of patients failing assisted ventilation. Secondary outcomes included safety, physiologic parameters in the first week from randomization, 28-day mortality, and ventilator-free days. Two-hundred and fifty-eight patients (31% women; median age, 65 [54-75] years) were enrolled. In the sigh group, 23% of patients failed to remain on assisted ventilation vs 30% in the no-sigh group (absolute difference, -7%; 95% CI, -18% to 4%; P = .015 for noninferiority). Adverse events occurred in 12% vs 13% in the sigh vs no-sigh group (P = .852). Oxygenation was improved whereas tidal volume, respiratory rate, and corrected minute ventilation were lower over the first 7 days from randomization in the sigh vs no-sigh group. There was no significant difference in terms of mortality (16% vs 21%; P = .337) and ventilator-free days (22 [7-26] vs 22 [3-25] days; P = .300) for the sigh vs no-sigh group. Among hypoxemic intubated ICU patients, application of sigh was feasible and without increased risk. ClinicalTrials.gov; No.: NCT03201263; URL: www.clinicaltrials.gov.